Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	MUTHU RAJA Karthick Raja KOVÁŘOVÁ Lucie HÁJEK Roman
Year of publication	2012
Type	Article in Periodical
Magazine / Source	Leukemia & Lymphoma
MU Faculty or unit	Faculty of Medicine
Citation
Doi	http://dx.doi.org/10.3109/10428194.2011.652106
Field	Oncology and hematology
Keywords	lenalidomide; dexamethasone; multiple myeloma
Attached files	Muthu_Raja_2012_-_Leuk_Lymph.pdf
Description	The introduction of novel drugs (thalidomide, lenalidomide [immunomodulatory drugs; IMiDs] and bortezomib) optimistically changed the outcome of patients with multiple myeloma (MM) in terms of progressionfree and overall survival when compared to conventional chemotherapies.
Related projects:	University Research Centre - Czech Myeloma Group From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies Vytvoření prognostického panelu u pacientů s monoklonální gamapatií nejasného významu s cílem zabránění transformace v maligní onemocnění Analýza klonálních progenitorů plazmatických buněk u monoklonálních gamapatií